In December 2022, 40+ community groups and an additional 45+ individuals released a community position statement calling on the global health community to take significant steps to institutionalize the recommendation of DRV/r for use in second-line (2L) treatment regimens.
The original community position statement, as well as a follow-up letter released in early 2023, cite the significant utilization of DRV/r in high-income countries, along with the many complaints regarding the side effects of LPV/r and ATV/r, the current protease inhibitors currently used widely in low- and middle-income countries.